TY  - JOUR
AU  - Paunović, Marija
AU  - Ristić-Medić, Danijela
AU  - Arsić, Aleksandra
AU  - Petrović, Snježana
AU  - Krstić, Predrag
AU  - Kojadinović, Milica
AU  - Vučić, Vesna
PY  - 2024
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1482
AB  - Background/Aim. Since the coronavirus disease 2019 (COVID-19) pandemic led to a strict lockdown in Serbia, the population has experienced drastic lifestyle changes. Physical distancing, self-isolation, limited availability of essential food products, and the stress related to the availability of therapy during the pandemic particularly affected the lives of vulnerable groups, such as breast cancer (BrC) patients. The aim of this study was to examine the changes in eating behaviors and physical activity of postmenopausal BrC patients on adjuvant hormonal therapy under the COVID-19 lockdown conditions. Methods. This observational retrospective pre-post cohort study included 32 women treated with aromatase inhibitors (AIs) who responded to telephone interviews using a structured questionnaire. The questionnaire aims to collect data on eating habits (intake of certain foods on a daily/weekly basis, as well as changes in the usual choice of food), intake of supplements, changes in weight, and physical activity before and during the lockdown. Results. The results showed that, due to problems in obtaining groceries, the patients cooked and consumed homemade sweets and fruit more often (47% of the respondents), while fewer (31%) consumed fresh fish. Nearly 41% of patients reported increased food intake, and 88% reported decreased physical activity, which led to an increase in body weight in as many as 47% of subjects. The intake of supplements was doubled. Conclusion. The COVID-19 lockdown with home confinement exacerbated health risks and affected dietary patterns and physical activity, which may have had a negative impact on the long-term health of BrC patients treated with AIs.
PB  - Military Medical Academy, INI
T2  - Vojnosanitetski pregled
T2  - Vojnosanitetski pregled
T1  - Eating behaviors and physical activity during the COVID-19 pandemic lockdown: Experiences of breast cancer patients on adjuvant hormonal therapy
EP  - xx
IS  - 00
SP  - xx
DO  - 10.2298/VSP231122020P
ER  - 

@article{
author = "Paunović, Marija and Ristić-Medić, Danijela and Arsić, Aleksandra and Petrović, Snježana and Krstić, Predrag and Kojadinović, Milica and Vučić, Vesna",
year = "2024",
abstract = "Background/Aim. Since the coronavirus disease 2019 (COVID-19) pandemic led to a strict lockdown in Serbia, the population has experienced drastic lifestyle changes. Physical distancing, self-isolation, limited availability of essential food products, and the stress related to the availability of therapy during the pandemic particularly affected the lives of vulnerable groups, such as breast cancer (BrC) patients. The aim of this study was to examine the changes in eating behaviors and physical activity of postmenopausal BrC patients on adjuvant hormonal therapy under the COVID-19 lockdown conditions. Methods. This observational retrospective pre-post cohort study included 32 women treated with aromatase inhibitors (AIs) who responded to telephone interviews using a structured questionnaire. The questionnaire aims to collect data on eating habits (intake of certain foods on a daily/weekly basis, as well as changes in the usual choice of food), intake of supplements, changes in weight, and physical activity before and during the lockdown. Results. The results showed that, due to problems in obtaining groceries, the patients cooked and consumed homemade sweets and fruit more often (47% of the respondents), while fewer (31%) consumed fresh fish. Nearly 41% of patients reported increased food intake, and 88% reported decreased physical activity, which led to an increase in body weight in as many as 47% of subjects. The intake of supplements was doubled. Conclusion. The COVID-19 lockdown with home confinement exacerbated health risks and affected dietary patterns and physical activity, which may have had a negative impact on the long-term health of BrC patients treated with AIs.",
publisher = "Military Medical Academy, INI",
journal = "Vojnosanitetski pregled, Vojnosanitetski pregled",
title = "Eating behaviors and physical activity during the COVID-19 pandemic lockdown: Experiences of breast cancer patients on adjuvant hormonal therapy",
pages = "xx-xx",
number = "00",
doi = "10.2298/VSP231122020P"
}

Paunović, M., Ristić-Medić, D., Arsić, A., Petrović, S., Krstić, P., Kojadinović, M.,& Vučić, V.. (2024). Eating behaviors and physical activity during the COVID-19 pandemic lockdown: Experiences of breast cancer patients on adjuvant hormonal therapy. in Vojnosanitetski pregled
Military Medical Academy, INI.(00), xx-xx.
https://doi.org/10.2298/VSP231122020P

Paunović M, Ristić-Medić D, Arsić A, Petrović S, Krstić P, Kojadinović M, Vučić V. Eating behaviors and physical activity during the COVID-19 pandemic lockdown: Experiences of breast cancer patients on adjuvant hormonal therapy. in Vojnosanitetski pregled. 2024;(00):xx-xx.
doi:10.2298/VSP231122020P .

Paunović, Marija, Ristić-Medić, Danijela, Arsić, Aleksandra, Petrović, Snježana, Krstić, Predrag, Kojadinović, Milica, Vučić, Vesna, "Eating behaviors and physical activity during the COVID-19 pandemic lockdown: Experiences of breast cancer patients on adjuvant hormonal therapy" in Vojnosanitetski pregled, no. 00 (2024):xx-xx,
https://doi.org/10.2298/VSP231122020P . .

TY  - JOUR
AU  - Arsić, Aleksandra
AU  - Krstić, Predrag
AU  - Paunović, Marija
AU  - Nedović, Jasmina
AU  - Jakovljević, Vladimir
AU  - Vučić, Vesna
PY  - 2023
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1313
AB  - Breast cancer is the most common malignant tumor and one of the leading causes of cancer-related death in women throughout the world. This study is a parallel, randomized, double-blind, controlled, 12-week supplementation trial, investigating the anti-inflammatory effects of dietary intake of fish oil and evening primrose oil (EPO), in patients with breast cancer undergoing chemotherapy. The primary outcomes were changes in the nutritional status and inflammatory cytokines of patients during the study. The secondary outcomes were changes in hematological and biochemical parameters and fatty acid profile. Of the 32 eligible patients, half of them is randomly assigned to a treatment arm with fish oil and EPO (n = 16), or a control arm (n = 16) with mineral oil as a placebo. The intervention group was taking 2 gel capsules of fish oil and 3 gel capsules of EPO (400 mg eicosapentaenoic acid, 600 mg docosahexaenoic acid, and 351 mg gamma-linolenic acid) fish oil and evening primrose oil for 12 weeks, during their chemotherapy. The control/placebo group was taking 5 gel capsules of 1g of mineral oil. One of the patients dropped out due to discontinuation of the treatment (in the placebo group) and two did not show up at the post-treatment measurements (in the intervention group), thus, 29 women completed the study. The results showed an increase in plasma levels of docosapentaenoic acid (22:5n-3), docosahexaenoic acid (22:6n-3), total n-3PUFA, vaccenic acid (18:1n-7), and a decrease in n-6/n-3 PUFA ratio in the intervention group. An increase in the plasma level of dihomo-gamma-linolenic acid (20:3n-6) was observed in the placebo group. There was no difference in plasma levels of interleukin (IL) IL-8, IL-10, and tumor necrosis factor-alpha, while the level of IL-6 decreased in both groups and was significantly lower in the intervention group at the end of the study. In conclusion, this supplementation improved the PUFA status and decreased the level of IL-6 in breast cancer patients undergoing chemotherapy. Consequently, this treatment may help reduce cancer complications resulting from impaired lipid metabolism and inflammation. ClinicalTrials.gov Identifier: NCT03516253. Date of registration 04/05/2018.
PB  - Springer Nature
T2  - Scientific Reports
T1  - Anti-inflammatory effect of combining fish oil and evening primrose oil supplementation on breast cancer patients undergoing chemotherapy: a randomized placebo-controlled trial
IS  - 1
SP  - 6449
VL  - 13
DO  - 10.1038/s41598-023-28411-8
ER  - 

@article{
author = "Arsić, Aleksandra and Krstić, Predrag and Paunović, Marija and Nedović, Jasmina and Jakovljević, Vladimir and Vučić, Vesna",
year = "2023",
abstract = "Breast cancer is the most common malignant tumor and one of the leading causes of cancer-related death in women throughout the world. This study is a parallel, randomized, double-blind, controlled, 12-week supplementation trial, investigating the anti-inflammatory effects of dietary intake of fish oil and evening primrose oil (EPO), in patients with breast cancer undergoing chemotherapy. The primary outcomes were changes in the nutritional status and inflammatory cytokines of patients during the study. The secondary outcomes were changes in hematological and biochemical parameters and fatty acid profile. Of the 32 eligible patients, half of them is randomly assigned to a treatment arm with fish oil and EPO (n = 16), or a control arm (n = 16) with mineral oil as a placebo. The intervention group was taking 2 gel capsules of fish oil and 3 gel capsules of EPO (400 mg eicosapentaenoic acid, 600 mg docosahexaenoic acid, and 351 mg gamma-linolenic acid) fish oil and evening primrose oil for 12 weeks, during their chemotherapy. The control/placebo group was taking 5 gel capsules of 1g of mineral oil. One of the patients dropped out due to discontinuation of the treatment (in the placebo group) and two did not show up at the post-treatment measurements (in the intervention group), thus, 29 women completed the study. The results showed an increase in plasma levels of docosapentaenoic acid (22:5n-3), docosahexaenoic acid (22:6n-3), total n-3PUFA, vaccenic acid (18:1n-7), and a decrease in n-6/n-3 PUFA ratio in the intervention group. An increase in the plasma level of dihomo-gamma-linolenic acid (20:3n-6) was observed in the placebo group. There was no difference in plasma levels of interleukin (IL) IL-8, IL-10, and tumor necrosis factor-alpha, while the level of IL-6 decreased in both groups and was significantly lower in the intervention group at the end of the study. In conclusion, this supplementation improved the PUFA status and decreased the level of IL-6 in breast cancer patients undergoing chemotherapy. Consequently, this treatment may help reduce cancer complications resulting from impaired lipid metabolism and inflammation. ClinicalTrials.gov Identifier: NCT03516253. Date of registration 04/05/2018.",
publisher = "Springer Nature",
journal = "Scientific Reports",
title = "Anti-inflammatory effect of combining fish oil and evening primrose oil supplementation on breast cancer patients undergoing chemotherapy: a randomized placebo-controlled trial",
number = "1",
pages = "6449",
volume = "13",
doi = "10.1038/s41598-023-28411-8"
}

Arsić, A., Krstić, P., Paunović, M., Nedović, J., Jakovljević, V.,& Vučić, V.. (2023). Anti-inflammatory effect of combining fish oil and evening primrose oil supplementation on breast cancer patients undergoing chemotherapy: a randomized placebo-controlled trial. in Scientific Reports
Springer Nature., 13(1), 6449.
https://doi.org/10.1038/s41598-023-28411-8

Arsić A, Krstić P, Paunović M, Nedović J, Jakovljević V, Vučić V. Anti-inflammatory effect of combining fish oil and evening primrose oil supplementation on breast cancer patients undergoing chemotherapy: a randomized placebo-controlled trial. in Scientific Reports. 2023;13(1):6449.
doi:10.1038/s41598-023-28411-8 .

Arsić, Aleksandra, Krstić, Predrag, Paunović, Marija, Nedović, Jasmina, Jakovljević, Vladimir, Vučić, Vesna, "Anti-inflammatory effect of combining fish oil and evening primrose oil supplementation on breast cancer patients undergoing chemotherapy: a randomized placebo-controlled trial" in Scientific Reports, 13, no. 1 (2023):6449,
https://doi.org/10.1038/s41598-023-28411-8 . .

TY  - JOUR
AU  - Krstić, Predrag
AU  - Vučić, Vesna M.
AU  - Paunović, Marija
AU  - Petrović, Snježana
AU  - Nedović, Nikola
AU  - Kostić, Sanja
AU  - Arsić, Aleksandra
PY  - 2021
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/1219
AB  - Background/Aim. Dysregulation of fatty acid (FA) me-tabolism is recognized as a component of malignant trans-formation in many cancers, including breast cancer (BC), and is often related to disease progression and prognosis. Adjuvant endocrine BC therapy using aromatase inhibitors may also influence FA metabolism. Thus, the aim of our study was to compare plasma total lipids FA status in new-ly diagnosed postmenopausal patients with BC and in postmenopausal women with BC receiving aromatase in-hibitors at least 2 years after completing chemotherapy with healthy women. Methods. The study included 17 newly diagnosed postmenopausal BC patients (ND group) and 21 postmenopausal women with BC receiving aroma-tase inhibitor therapy 2 years after ending chemotherapy (AI group), while a total of 15 apparently healthy women without a family history of BC, comparable in age and body mass index, served as a control group. Results. In both patient groups, we found significantly lower levels of vaccenic acid (18:1n-7), alpha-linolenic acid (18:3n-3), gamma-linolenic acid (GLA, 18:3n-6), and docosapentae-noic acid (22:5n-3), and a significantly higher level of di-homo-gamma-linolenic (20:3n-6), when compared with the control group. On the other hand, a significantly lower level of stearic acid (18:0) was observed only in AI pa-tients, while the level of linoleic acid (18:2n-6) was signifi-cantly higher in ND women than in the control group. Reduced estimated activities of D6 and D5 desaturases were found in both patient groups than in the control group. Conclusion. Our results indicate that FA profiles of plasma lipids of the newly diagnosed, untreated BC pa-tients are very similar to those of cured BC patients who underwent all sessions of chemotherapy and received aromatase inhibitors for at least two years. Additionally, according to our results, their FA profiles markedly differ from those of healthy women. Therefore, supplementation with omega-3 FA and GLA could have beneficial effects in these patients, and further studies should address the potential clinical benefits of the supplementation.
AB  - Uvod/Cilj. Promene u metabolizmu masnih kiselina prepoznate su kao komponenta maligne transformacije u mnogim različitim vrstama kancera, uključujući i karcinom dojke (KD), a često su povezane sa progresijom i prognozom bolesti. Adjuvantna endokrina terapija KD, korišćenjem inhibitora aromataze, takođe može uticati na metabolizam masnih kiselina (MK). Zbog toga je cilj ovog rada bio da se uporede MK profili iz ukupnih lipida plazme kod žena u menopauzi, a kojima je dijagnostikovan KD, i onih sa KD koje su na terapiji inhibitorima aromataze najmanje dve godine, sa MK profilima kontrolne grupe. Metode. U studiju je bilo uključeno 17 žena sa novodijag- nostikovanim KD (ND grupi) i 21 žena sa KD koje su na terapiji inhibitorima aromataze (AI grupi). Kontrolnu grupu je činilo 15 uslovno zdravih žena u menopauzi koje nisu imale porodičnu anamnezu za KD i koje su po godinama i indeksu telesne mase poređene sa bolesnicama. Rezultati. Procenat vakcenske (18:1n-7), alfa-linolenske (18:3n-3), ga- ma-linolenske (18:3n-6) i dokozapentaenske (22:5n-3) kis- eline bio je značajno niži, dok je procenat dihomo-gama- linolenske kiseline (20:3n-6) bio značajno viši, kod obe grupe bolesnica u odnosu na kontrolnu grupu. Sa druge strane, niži nivo stearinske kiseline (18:0) pronašli smo u samo AI grupi, dok je visok nivo linolne kiseline (18:2n-6) utvrđen samo u ND grupi u odnosu na kontrolu. Smanjena procenjena ak- tivnost D6 i D5 desaturaze nađena je kod obe grupe bolesni- ca u odnosu na kontrolnu grupu. Zaključak. Naši rezultati su pokazali veoma sličan MK profil kod žena sa tek dijagnos- tikovanim KD i onih koje su na terapiji inhibitorima aroma- taze najkraće dve godine, ali i da se njihovi MK profili u ve- likoj meri razlikuju od MK profila kontrolne grupe. Zbog to- ga, suplementacija n-3 masnim kiselinama i gama linolenskom kiselinom može biti korisna za ove bolesnice, i buduće studije bi mogle ispitivati potencijalnu korist ovih suplemenata.
PB  - Vojnomedicinska akademija, Institut za naučne informacije
T2  - Vojnosanitetski pregled
T1  - Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy
T1  - Sličan masnokiselinski status kod žena sa novodijagnostikovanim karcinomom
dojke i onih koje su na terapiji inhibitorima aromataze
EP  - 1145
IS  - 11
SP  - 1140
VL  - 78
DO  - 10.2298/VSP200124032K
ER  - 

@article{
author = "Krstić, Predrag and Vučić, Vesna M. and Paunović, Marija and Petrović, Snježana and Nedović, Nikola and Kostić, Sanja and Arsić, Aleksandra",
year = "2021",
abstract = "Background/Aim. Dysregulation of fatty acid (FA) me-tabolism is recognized as a component of malignant trans-formation in many cancers, including breast cancer (BC), and is often related to disease progression and prognosis. Adjuvant endocrine BC therapy using aromatase inhibitors may also influence FA metabolism. Thus, the aim of our study was to compare plasma total lipids FA status in new-ly diagnosed postmenopausal patients with BC and in postmenopausal women with BC receiving aromatase in-hibitors at least 2 years after completing chemotherapy with healthy women. Methods. The study included 17 newly diagnosed postmenopausal BC patients (ND group) and 21 postmenopausal women with BC receiving aroma-tase inhibitor therapy 2 years after ending chemotherapy (AI group), while a total of 15 apparently healthy women without a family history of BC, comparable in age and body mass index, served as a control group. Results. In both patient groups, we found significantly lower levels of vaccenic acid (18:1n-7), alpha-linolenic acid (18:3n-3), gamma-linolenic acid (GLA, 18:3n-6), and docosapentae-noic acid (22:5n-3), and a significantly higher level of di-homo-gamma-linolenic (20:3n-6), when compared with the control group. On the other hand, a significantly lower level of stearic acid (18:0) was observed only in AI pa-tients, while the level of linoleic acid (18:2n-6) was signifi-cantly higher in ND women than in the control group. Reduced estimated activities of D6 and D5 desaturases were found in both patient groups than in the control group. Conclusion. Our results indicate that FA profiles of plasma lipids of the newly diagnosed, untreated BC pa-tients are very similar to those of cured BC patients who underwent all sessions of chemotherapy and received aromatase inhibitors for at least two years. Additionally, according to our results, their FA profiles markedly differ from those of healthy women. Therefore, supplementation with omega-3 FA and GLA could have beneficial effects in these patients, and further studies should address the potential clinical benefits of the supplementation., Uvod/Cilj. Promene u metabolizmu masnih kiselina prepoznate su kao komponenta maligne transformacije u mnogim različitim vrstama kancera, uključujući i karcinom dojke (KD), a često su povezane sa progresijom i prognozom bolesti. Adjuvantna endokrina terapija KD, korišćenjem inhibitora aromataze, takođe može uticati na metabolizam masnih kiselina (MK). Zbog toga je cilj ovog rada bio da se uporede MK profili iz ukupnih lipida plazme kod žena u menopauzi, a kojima je dijagnostikovan KD, i onih sa KD koje su na terapiji inhibitorima aromataze najmanje dve godine, sa MK profilima kontrolne grupe. Metode. U studiju je bilo uključeno 17 žena sa novodijag- nostikovanim KD (ND grupi) i 21 žena sa KD koje su na terapiji inhibitorima aromataze (AI grupi). Kontrolnu grupu je činilo 15 uslovno zdravih žena u menopauzi koje nisu imale porodičnu anamnezu za KD i koje su po godinama i indeksu telesne mase poređene sa bolesnicama. Rezultati. Procenat vakcenske (18:1n-7), alfa-linolenske (18:3n-3), ga- ma-linolenske (18:3n-6) i dokozapentaenske (22:5n-3) kis- eline bio je značajno niži, dok je procenat dihomo-gama- linolenske kiseline (20:3n-6) bio značajno viši, kod obe grupe bolesnica u odnosu na kontrolnu grupu. Sa druge strane, niži nivo stearinske kiseline (18:0) pronašli smo u samo AI grupi, dok je visok nivo linolne kiseline (18:2n-6) utvrđen samo u ND grupi u odnosu na kontrolu. Smanjena procenjena ak- tivnost D6 i D5 desaturaze nađena je kod obe grupe bolesni- ca u odnosu na kontrolnu grupu. Zaključak. Naši rezultati su pokazali veoma sličan MK profil kod žena sa tek dijagnos- tikovanim KD i onih koje su na terapiji inhibitorima aroma- taze najkraće dve godine, ali i da se njihovi MK profili u ve- likoj meri razlikuju od MK profila kontrolne grupe. Zbog to- ga, suplementacija n-3 masnim kiselinama i gama linolenskom kiselinom može biti korisna za ove bolesnice, i buduće studije bi mogle ispitivati potencijalnu korist ovih suplemenata.",
publisher = "Vojnomedicinska akademija, Institut za naučne informacije",
journal = "Vojnosanitetski pregled",
title = "Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy, Sličan masnokiselinski status kod žena sa novodijagnostikovanim karcinomom
dojke i onih koje su na terapiji inhibitorima aromataze",
pages = "1145-1140",
number = "11",
volume = "78",
doi = "10.2298/VSP200124032K"
}

Krstić, P., Vučić, V. M., Paunović, M., Petrović, S., Nedović, N., Kostić, S.,& Arsić, A.. (2021). Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy. in Vojnosanitetski pregled
Vojnomedicinska akademija, Institut za naučne informacije., 78(11), 1140-1145.
https://doi.org/10.2298/VSP200124032K

Krstić P, Vučić VM, Paunović M, Petrović S, Nedović N, Kostić S, Arsić A. Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy. in Vojnosanitetski pregled. 2021;78(11):1140-1145.
doi:10.2298/VSP200124032K .

Krstić, Predrag, Vučić, Vesna M., Paunović, Marija, Petrović, Snježana, Nedović, Nikola, Kostić, Sanja, Arsić, Aleksandra, "Similar fatty acid status of plasma lipids in postmenopausal women newly diagnosed with breast cancer and those receiving aromatase inhibitor therapy" in Vojnosanitetski pregled, 78, no. 11 (2021):1140-1145,
https://doi.org/10.2298/VSP200124032K . .